Global Carbidopa Market Worth $ 370 Million by 2019

Date: 2016-09-10

Carbidopa is a drug given to people with Parkinson’s disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect.

Parkinson’s disease is the main application of carbidopa product and North American is the largest carbidopa market on production and consumption.

What is Parkinson’s disease?

Parkinson’s disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson’s disease.

Global carbidopa market is projected to reach $ 370 Million by 2019, with a GAGR of 2.7% from 2015, and Asia will have a big dynamic momentum on the market growth. The major players in the global carbidopa market are Chiral Medicine, Wild Wind, MERCK, BMS, Novartis etc..


Read Full Report:

Joanna | Executive – International Business and partner Relations
E-mail: | Tel: 1-510-400-8520

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample